Morepen Laboratories Limited (NSE: MOREPENLAB; BSE: 500288) has announced the successful completion of an inspection by the US Â Food and Drug Administration (USFDA) at its Masulakhanna facility in Himachal Pradesh, with zero observations (NIL Form 483). This marks the fourth consecutive clean inspection for the company over the past eight years, reflecting sustained adherence to stringent global regulatory standards.
The outcome highlights the company’s strong quality management systems, consistent compliance practices, and focus on maintaining high standards across its manufacturing operations. A NIL Form 483 indicates that no observations were made by the regulator during the inspection, a benchmark widely regarded as a significant achievement in the pharmaceutical industry.
Sanjay Suri, Executive Director of Morepen Laboratories, stated that the repeated success in regulatory inspections demonstrates the company’s disciplined approach to quality and compliance. He added that such outcomes strengthen trust among global regulators, customers, and partners, while also supporting long-term business opportunities, including supply agreements in regulated markets.
Morepen has aligned its operations with evolving global regulatory frameworks, including guidelines under International Council for Harmonisation (ICH) and Code of Federal Regulations standards, ensuring high levels of product safety, efficacy, and consistency. The company’s emphasis on data integrity, process standardization, and continuous improvement has played a key role in maintaining this track record.
With exports spanning more than 80 countries, Morepen continues to serve major pharmaceutical markets in the United States, Europe, and other regions. Its manufacturing facilities are regularly audited by global clients, reinforcing its position as a reliable supplier of active pharmaceutical ingredients (APIs).
In recent years, the company has also invested significantly in digital transformation initiatives, including automation and advanced data management systems. These efforts have improved traceability, operational efficiency, and transparency across manufacturing and quality processes, aligning with international regulatory expectations.
Recognized as a market leader in several key API segments, Morepen is now expanding its presence in the contract development and manufacturing organization (CDMO) space. This strategic move is aimed at leveraging its regulatory track record, technical expertise, and infrastructure to tap into new growth opportunities.
Morepen Laboratories operates as a vertically integrated pharmaceutical and healthcare company, with a diversified portfolio that includes APIs, formulations, medical devices, and consumer wellness products. With a strong global footprint and multiple regulatory approvals, the company remains focused on delivering quality healthcare solutions while advancing innovation and accessibility across markets.
